Ipamorelin

Ipamorelin is a synthetic pentapeptide and selective growth hormone secretagogue receptor agonist (GHS-R1a), first described by Raun et al. in the European Journal of Endocrinology (1998). It is widely used in GH axis research for its exceptional receptor selectivity — activating GHS-R1a with minimal cross-reactivity at ACTH, prolactin, or aldosterone receptor pathways, making it a significantly cleaner pharmacological tool than earlier GHRPs such as GHRP-2, GHRP-6, or Hexarelin.

Molecular formula: C38H49N9O5 | Molecular weight: 711.85 g/mol | CAS: 170851-70-4 | Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH2 | Amino acids: 5 | Purity: greater than or equal to 98% as verified by HPLC | Form: Lyophilised powder | Appearance: White to off-white lyophilised powder | Storage: -20°C desiccated

Three non-natural amino acid modifications confer metabolic stability: Aib (alpha-aminoisobutyric acid) at position 1 blocks DPP-IV cleavage; D-2-Naphthylalanine at position 3 and D-Phenylalanine at position 4 resist L-specific peptidases. C-terminal amidation (Lys-NH2) prevents carboxypeptidase degradation. Together these modifications extend stability in biological research media without compromising GHS-R1a binding affinity.

GHS-R1a activation via Gq/11 coupling triggers IP3-mediated calcium release and PKC activation, producing pulsatile GH release that mirrors physiological GH secretion dynamics. This contrasts with sustained GH elevation from CJC-1295 (With DAC), enabling direct pharmacodynamic comparison studies. Ipamorelin is frequently paired with CJC-1295 (No DAC) for dual-receptor GH axis research.

Supplied as a lyophilised powder. Reconstitute with bacteriostatic water. Store at -20°C protected from light and moisture. For laboratory and analytical research purposes only. Not for human or veterinary use.